Results 1 to 10 of about 2,566,443 (193)
Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review [PDF]
Pharmaceuticals, 2023 Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi.
Adwoa Dansoa Tabi-Amponsah +5 more
doaj +8 more sources
Urate-lowering therapy and kidney function [PDF]
Современная ревматология, 2023 Chronic hyperuricemia (CH) and gout are independent risk factors for decreased kidney function. In the last decade, evidence was accumulating that urate-lowering therapy may be an effective method of slowing down the progression of CH and gout-mediated ...
M. S. Eliseev
doaj +3 more sources
Urate-lowering therapy for heart failure
Современная ревматология, 2019 Heart failure (HF) is one of the major public health problems in developed countries. Hyperuricemia (HU) is often found in patients with chronic HF (CHF) and is a well-known independent predictor for mortality and re-hospitalization for the progression ...
O. V. Zhelyabina, M. S. Eliseev
doaj +3 more sources
PLoS ONE, 2019 Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj +2 more sources
Urate-lowering drugs in the treatment of gout: The unknown about the known [PDF]
Научно-практическая ревматология, 2021 The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin +2 more
doaj +2 more sources
Frontiers in Pharmacology, 2022 Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda +15 more
doaj +1 more source
The many faces of gout: modern treatment concepts
Клинический разбор в общей медицине, 2021 Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation.
Irina N. Bobkova, Elena S. Kamyshova
doaj +1 more source
Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway
Nutrition & Metabolism, 2021 Objectives The study of sex differences in hyperuricemia can provide not only a theoretical basis for this clinical phenomenon but also new therapeutic targets for urate-lowering therapy.
Lei Liu +5 more
doaj +1 more source
Contentious Issues in Gout Management: The Story so Far
Open Access Rheumatology: Research and Reviews, 2021 Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019 ...
Talaat M, Park K, Schlesinger N
doaj
Experience with canakinumab in a patient with gout and IgA nephropathy
Современная ревматология, 2019 The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj +1 more source